A MULTIPLE sclerosis sufferer from Taunton has welcomed a potential breakthrough in finding treatments for the devastating condition.

Scientists have found a new cellular mechanism which may cause the disease and a potential hallmark which could be a target for future treatment of the autoimmune disorder.

Multiple sclerosis affects around 2.5 million people around the world.

Typically, people are diagnosed in their 20s and 30s, and it is more common in women than men.

Although the cause has so far been a mystery, the disease causes the body's own immune system to attack myelin - the fatty "sheaths" which protect nerves in the brain and spinal cord.

This leads to brain damage, a reduction in blood supply and oxygen and the formation of lesions in the body.

Symptoms can be wide-ranging, and can include muscle spasms, mobility problems, pain, fatigue, and problems with speech.

Claire Thackray from Taunton suddenly went blind in one eye at the age of 25.

Now 32, Ms Thackray initially put it down to crying too much after a break-up.

Her vision was affected for a month, and medical investigations initially drew a blank - but within months, MS was identified as the cause.

"I was completely floored," said Ms Thackray.

"There's no history of MS in my family - it hadn't occurred to me at all. Initially I thought my life was over, and that I was on a downward spiral to disability and a wheelchair.

"Thankfully, that hasn't been the case at all."

Using human brain tissue samples, researchers at the Universities of Exeter and Alberta found a protein called Rab32 is present in large quantities in the brains of people with MS - but is virtually absent in healthy brain cells.

Where Rab32 is present, the team discovered that a part of the cell which stores calcium gets too close to the mitochondria.

The resulting miscommunication with the calcium supply triggers the mitochondria to misbehave, ultimately causing toxicity for brain cells in people with MS.

Researchers do not yet know what causes an unwelcome influx of Rab32 but they believe the defect could originate at the base of the cell.

Ms Thackray added: "I really welcome this new research - it's really important to move forward in our understanding about what goes on in the brain in people with MS."

Ms Thackray manages her symptoms through medication and maintaining a healthy lifestyle and has found that her symptoms have so far stabilised, with no further decline.

Her experience prompted her to re-prioritise her life. She left her job as a teacher and now works for Taunton Deane Borough council.

"I feel I'm one of the lucky ones," she said.

"I was diagnosed early enough to take measures to help me maintain a good lifestyle and work-life balance.

"I'm a fitness fan and I'm still physically active. Every day that I can see and walk is a good day for me."

She is inspired by Paralympic swimmer Stephanie Millward and writer and novelist Hilary Freeman.

Both have MS, and Ms Thackray is hoping they will both contribute to an upcoming book she has written about her experience, to help support people who receive a relapsing-remitting diagnosis.

The finding will enable scientists to search for effective treatments that target Rab32 and embark on determining whether there are other proteins which could pay a role in triggering MS.

Professor Paul Eggleton, of the University of Exeter Medical School, said: "Multiple sclerosis can have a devastating impact on people's lives, affecting mobility, speech, mental ability and more.

"So far, all medicine can offer is treatment and therapy for the symptoms - as we do not yet know the precise causes, research has been limited.

"Our exciting new findings have uncovered a new avenue for researchers to explore. It is a critical step, and in time, we hope it might lead to effective new treatments for MS."

The research has been published as part of MS Awareness Week.

Dr David Schley, from the MS Society, said: "No-one knows for sure why people develop MS and we welcome any research that increases our understanding of how to stop it.

"There are currently no treatments available for many of the more than 100,000 people in the UK who live with this challenging and unpredictable condition.

"We want people with MS to have a range of treatments to choose from, and be able to get the right treatment at the right time."